COYA
Coya Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Coya Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Coya Therapeutics has 15 disclosed suppliers and 1 disclosed customer in SEC filings.
Coya Therapeutics, Inc.
3.68
SentenceFor example, to image the exosomes we will rely on Malvern, to measure the size of the exosomes we will rely on Izon, for western blotting we will rely on ThermoFisher, for mass spectrometry we will rely on Applied Biosystems, and for DNA tethering materials we will rely on multiple manufacturers.
SentenceFor example, to image the exosomes we will rely on Malvern, to measure the size of the exosomes we will rely on Izon, for western blotting we will rely on ThermoFisher, for mass spectrometry we will rely on Applied Biosystems, and for DNA tethering materials we will rely on multiple manufacturers.
COYA 10-Kaccession 0001193125-26-107281
SentenceIn August 2022, we entered into a License Agreement (the "ARS License Agreement") with ARS pursuant to which ARS granted us an option to, if we choose to exercise such option, to acquire an exclusive, royalty-bearing license for two patents regarding certain formulations of IL-2 (the product that serves as the basis for COYA 301), with the right to grant sublicenses through multiple tiers under these patents.
COYA 10-Kaccession 0001193125-26-107281
SentenceFor COYA 301, we have licensed the biologic cytokine from ARScience Biotherapeutics, Inc. and will rely on its manufacturing of the subject cytokine.
COYA 10-Kaccession 0001193125-26-107281
SentenceFinally, our patent estate derived from our relationship with Carnegie Mellon included one pending patent application.
COYA 10-Kaccession 0001193125-26-107281
SentenceIn September of 2023 we licensed the exclusive, worldwide rights of a proprietary Exosome Engineering Technology from Carnegie Mellon University with potential applications across multiple indications, including neurodegeneration, autoimmune, and oncology (the "Carnegie Mellon License Agreement").
COYA 10-Kaccession 0001193125-26-107281
SentenceIn May 2023, we executed a Sponsored Research Agreement, or SRA, with Houston Methodist Research Institute, or HMRI, in which we agreed to fund approximately $0.5 million through May 2024.
COYA 10-Kaccession 0001193125-26-107281
SentenceFor example, to image the exosomes we will rely on Malvern, to measure the size of the exosomes we will rely on Izon, for western blotting we will rely on ThermoFisher, for mass spectrometry we will rely on Applied Biosystems, and for DNA tethering materials we will rely on multiple manufacturers.
COYA 10-Kaccession 0001193125-26-107281
SentenceFor example, to image the exosomes we will rely on Malvern, to measure the size of the exosomes we will rely on Izon, for western blotting we will rely on ThermoFisher, for mass spectrometry we will rely on Applied Biosystems, and for DNA tethering materials we will rely on multiple manufacturers.
COYA 10-Kaccession 0001193125-26-107281
SentenceFor COYA 201, we rely on Terumo BCT to manufacture the Terumo Bioreactors to generate the appropriate number of expanded Treg cells.
COYA 10-Kaccession 0001193125-26-107281
SentenceKey components of the technology utilized in our Treg Modalities have been in-licensed pursuant to an Amended and Restated Patent and Know How License Agreement, (the "Methodist License Agreement"), between us and The Methodist Hospital located in Houston, Texas (the "Methodist").
COYA 10-Kaccession 0001193125-26-107281
SentenceKey components of the technology utilized in our Treg Modalities have been in-licensed pursuant to an Amended and Restated Patent and Know How License Agreement, (the "Methodist License Agreement"), between us and The Methodist Hospital located in Houston, Texas (the "Methodist").
COYA 10-Kaccession 0001193125-26-107281
Sentenceour patent estate derived from our relationship with the University of Nebraska includes two provisional patent applications.
COYA 10-Kaccession 0001193125-26-107281
Linked news
Expected move
No implied move.